Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.

ABSTRACT:

Background

Men on active surveillance (AS) face repeated biopsies. Most biopsy specimens will not show disease progression or change management. Such biopsies do not contribute to patient management and are potentially morbid and costly.

Objective

To use a contemporary AS prospective trial to develop a tool to predict AS biopsy outcomes.

Design, setting, and participants

Biopsy samples (median: 2; range: 2-9 per patient) from 859 men participating in the Canary Prostate Active Surveillance Study and with Gleason 6 prostate cancer (median follow-up: 35.8 mo; range: 3.0-148.7 mo) were analyzed.

Outcome measurements and statistical analysis

Logistic regression was used to predict progression, defined as an increase in Gleason score from ≤6 to ≥7 or increase in per

SUBMITTER: Ankerst DP 

PROVIDER: S-EPMC4583313 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature